Medherant announces positive Phase I results for its first transdermal drug delivery patch
- On November 15, 2018
- By GrowthInvest Admin
National investment group Mercia Technologies PLC, one of the UK’s most active technology investors, is pleased to announce that its direct investment Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.
The TEPI Patch was shown to be well tolerated by all subjects in a study of skin irritation and sensitisation. This marks the first clinical safety evaluation of Medherant’s novel adhesive, facilitating the development of the next generation of drug-in-adhesive patches.
In the second study, concentrations of ibuprofen in the blood following repeated application of the Ibuprofen TEPI Patch and a single oral dose of ibuprofen were compared. As expected, blood levels were significantly lower after application of the patch reflecting its design as a local delivery mechanism. Local application provides site-specific pain relief and a lower blood concentration will help minimise side effects.
For more information and to read the full article, please click here
GET IN TOUCH!
CALL US020 7071 3945
FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.